New sleep aid shows promise for night shift workers
NCT ID NCT05344443
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a medication called lemborexant can help night shift workers sleep longer during the day. 29 full-time night shift workers who had trouble sleeping took either the drug or a placebo for two weeks. The goal was to see if the drug increased total daytime sleep time.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
29 people
The number who actually took part.
- Started
-
Mar 2022
- Finished
-
Nov 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
20 to 60 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Full-time night shift work (at least 6 hours per shift, 4 days per week or 32 hours per week) * Employed as a night shift worker for at least 3 months * Self-reported concerns about daytime sleepiness and difficulty sleeping during the daytime Exclusion Criteria: * Pregnancy (verified by urine pregnancy test) or plan to become pregnant in the next 3 months * Currently breastfeeding * Inadequate opportunity for sleep during the daytime (\< 7 hours opportunity) after overnight shift * Extreme circadian preference (based on Horne \& Ostberg Morningness-Eveningness Questionnaire) * Severe depressive symptoms (\>25 on CES-D) * Unwillingness to discontinue sleep aids (prescription or non-prescription) during the study period * Presence of sleep disordered breathing (verified by Apnea link) * Self-reported diagnosis of narcolepsy, restless legs syndrome * Self-reported intake of \>600mg of caffeine per night shift or use of stimulants during night shift, rotational, or irregular shifts * Unstable or untreated medical or psychiatric condition based on clinical interview. * Severe hepatic or renal impairment (based on chemistry panel); * Self-reported use of digoxin or strong or moderate cytochrome P450 3A4 isozyme inhibitors or cytochrome P450 3A4 isozyme inducers for 6 months prior to or during the study
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Shift-work related sleep disturbance are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of California, San Francisco
San Francisco, California, 94143, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.